Current Allergy and Asthma Reports

, Volume 12, Issue 2, pp 85–98

Clinical Overview of Cutaneous Features in Hypereosinophilic Syndrome

  • Sabine Gisela Plötz
  • Bettina Hüttig
  • Birgit Aigner
  • Christian Merkel
  • Knut Brockow
  • Cezmi Akdis
  • Ulf Darsow
  • Johannes Ring
Invited Commentary

Abstract

The hypereosinophilic syndromes (HES) are a heterogeneous group of disorders defined as persistent and marked blood eosinophilia of unknown origin with systemic organ involvement. HES is a potentially severe multisystem disease associated with considerable morbidity. Skin involvement and cutaneous findings frequently can be seen in those patients. Skin symptoms consist of angioedema; unusual urticarial lesions; and eczematous, therapy-resistant, pruriginous papules and nodules. They may be the only obvious clinical symptoms. Cutaneous features can give an important hint to the diagnosis of this rare and often severe illness. Based on advances in molecular and genetic diagnostic techniques and on increasing experience with characteristic clinical features and prognostic markers, therapy has changed radically. Current therapies include corticosteroids, hydroxyurea, interferon-α, the tyrosine kinase inhibitor imatinib mesylate, and (in progress) the monoclonal anti–interleukin-5 antibodies. This article provides an overview of current concepts of disease classification, different skin findings, and therapy for HES.

Keywords

Hypereosinophilic syndrome (HES) Cutaneous Urticaria Angioedema Eczema Immunologic diseases Eosinophilia 

References

  1. 1.
    Griffin H. Persistant eosinophilia with hyperleucocytosis and splenomegaly. Am J Med Sci. 1919;158:618–29.Google Scholar
  2. 2.
    Hardy WR, Anderson R. The hypereosinophilic syndrome. Ann Intern Med Sci. 1968;158:618–29.Google Scholar
  3. 3.
    Weller PF. Eosinophils: structure and functions. Curr Opin Immunol. 1994;6:85–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759–79.PubMedGoogle Scholar
  5. 5.
    Spry CJ. The hypereosinophilic syndrome: clinical features, laboratory findings and treatment. Allergy. 1982;37(8):539–51.PubMedCrossRefGoogle Scholar
  6. 6.
    Weller PF, Dvorak AM. The idiopathic hypereosinophilic syndrome. Arch Dermatol. 1996;132:583–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Gleich GJ, Schroeter AL, Marcoux P, et al. Episodic angioedema associated with eosinophilia. N Engl J Med. 1984;310:1621–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Sheikh J, Weller PF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):333–55.PubMedCrossRefGoogle Scholar
  9. 9.
    Chusid MJ, Dale CD, West BC. The hypereosinophilic syndrome: analysis of 14 cases with review of the literature. Medicine. 1975;54:1–27.PubMedCrossRefGoogle Scholar
  10. 10.
    Sheikh J, Weller PF. Advances in diagnosis &treatment of eosinophilia. Curr Opin Hematol. 2009;16(1):3–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Schwartz LB, Sheikh J, Singh A. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. Curr Med Res Opin. 2010;26(8):1933–46.PubMedCrossRefGoogle Scholar
  12. 12.
    Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME, Rosenwasser LJ, Roufosse F, Gleich GJ, Klion AD. Refining the definition of hypereosinophilic syndrome. JACI. 2010;126(1):45–9.Google Scholar
  13. 13.
    Roufosse F, Goldman M, Cogan E. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Semin Respir Crit Care Med. 2006;27:158–70.PubMedCrossRefGoogle Scholar
  14. 14.
    Ring J. Allergy in practice. New York: Springer Berlin; 2005.Google Scholar
  15. 15.
    Ring J, Ruzicka T, Przybilla B, editors. Handbook of atopic eczema. 2nd ed. New York: Springer Berlin; 2006.Google Scholar
  16. 16.
    Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med. 2003;54:169–84.PubMedCrossRefGoogle Scholar
  17. 17.
    Roufosse F, Cogan E, Goldman M. Recent advances in the pathogenesis and management of hypereosinophilic syndromes. Allergy. 2004;59:673–89.PubMedCrossRefGoogle Scholar
  18. 18.
    Roufosse F, Cogan E, Goldman M. Lymphocytic variant of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):389–413.PubMedCrossRefGoogle Scholar
  19. 19.
    Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341(15):1112–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Plötz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349(24):2334–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Cools J, De Angelo D, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGRA and FIP1L1 genes as therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101(12):4660–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Klion AD, Bochner BS, Gleich GJ, et al. The Hypereosinophilic Syndromes Working Group. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol. 2006;117(6):1292–302.PubMedCrossRefGoogle Scholar
  24. 24.
    Reiter A, Grimwade D, Cross NC. Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. Haematologica. 2007;92(9):1153–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Reiter A, Inverbizzi R, Cross NC, Cazzola M. Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2009;94(12):1634–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Gleich GF, Leifermann KM, Pardanani A, et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Valent P. Pathogenesis, classification and therapy of eosinophilia and eosinophilic disorders. Blood Rev Med. 2003;23:157–65.CrossRefGoogle Scholar
  28. 28.
    Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukaemia, and systemic mastocytosis. Am J Hematol. 2004;77(1):82–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Leiferman KM, Gleich GJ. Hypereosinophilic syndrome: case presentation and update. J Allergy Clin Immunol. 2004;113(1):50–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Leiferman KM, O’Duffy JD, Perry HO, et al. Recurrent incapacitating mucosal ulcerations. A prodrome of the hypereosinophilic syndrome. JAMA. 1982;247(7):1018–20.PubMedCrossRefGoogle Scholar
  31. 31.
    Leiferman KM, Gleich GJ, Peters MS. Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):415–41.PubMedCrossRefGoogle Scholar
  32. 32.
    Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215–28.PubMedCrossRefGoogle Scholar
  33. 33.
    Sanderson CJ. Pharmacological implications of interleukin-5 in the control of eosinophilia. Adv Pharmacol. 1992;23:163–77.PubMedCrossRefGoogle Scholar
  34. 34.
    Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79(12):3101–9.PubMedGoogle Scholar
  35. 35.
    Cogan E, Schandene L, Crusiaux A, et al. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994;330:535–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Simon HU, Yousefi S, Dommann-Scherrer C, et al. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med. 1996;183:1071–82.PubMedCrossRefGoogle Scholar
  37. 37.
    Roufosse F, Schadene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Hematol. 2000;109:540–8.CrossRefGoogle Scholar
  38. 38.
    Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, et al. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica. 2009;94:1236–41.PubMedCrossRefGoogle Scholar
  39. 39.
    Plötz SG, Dibbert B, Abeck D, et al. Bcl-2 expression by eosinophils in a patient with hypereosinophilia. J Allergy Clin Immunol. 1998;102:1037–40.PubMedCrossRefGoogle Scholar
  40. 40.
    Roufosse F. Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations. Haematologica. 2009;94:1188–93.PubMedCrossRefGoogle Scholar
  41. 41.
    Spry CJ, Kay AB, Gleich GJ. Eosinophils. Immunol Today. 1992;13:384–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Plotz SG, Abeck D, Seitzer U, Hein R, Ring J. UVA1 for hypereosinophilic syndrome. Acta Derm Venereol. 2000;80:221.PubMedCrossRefGoogle Scholar
  43. 43.
    De Lavareille A, Roufosse F, Schmid-Grendelmeier P, et al. High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol. 2002;110:476–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Simon HU, Plotz SG, Simon D, et al. Clinical and immunological features of patients with interleukin-5-producing T cell clones and eosinophilia. Int Arch Allergy Immunol. 2001;124(1–3):242–5.PubMedCrossRefGoogle Scholar
  45. 45.
    O’Shea JJ, Jaffe ES, Lane HC, et al. Peripheral T cell lymphoma presenting as hypereosinophilia with vasculitis. Clinical, pathologic, and immunologic features. Am J Med. 1987;82(3):539–45.PubMedCrossRefGoogle Scholar
  46. 46.
    Moraillon I, Bagot M, Bourneriaas I, et al. Hypereosinophilic syndrome with pachyderma preceding lymphoma. Treatment with interferon alpha. Acta Derm Venereol. 1991;118(11):883–5.Google Scholar
  47. 47.
    Kim CJ, Park SH, Chi JG. Idiopathic hypereosinophilic syndrome terminating as disseminated T-cell lymphoma. Cancer. 1991;67(4):1064–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol. 2007;119:1291–300.PubMedCrossRefGoogle Scholar
  49. 49.
    Fauci AS, Harley JB, Roberts WC, et al. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic and therapeutic considerations. Ann Intern Med. 1982;97(1):78–91.PubMedGoogle Scholar
  50. 50.
    Parillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978;89:167–72.Google Scholar
  51. 51.
    Kazmierowski JA, Chusid MJ, Parillo JE, et al. Dermatologic manifestations of the hypereosinophilic syndrome. Arch Dermatol. 1978;114:531–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Shelley WB, Shelley ED. Erythema annulare centrifugum as the presenting sign of the hypereosinophilic syndrome. Cutis. 1985;35:53–8.PubMedGoogle Scholar
  53. 53.
    Milijkovic J, Bartenev I. Hypereosinophilic dermatitis-like erythema annulare centrifugum in a patient with chronic lymphocytic leukaemia. J Eur Acad Dermatol Venereol. 2005;19(2):228–31.CrossRefGoogle Scholar
  54. 54.
    Ohtani T, Okamoto K, Kaminaka C, et al. Digital gangrene associated with idiopathic hypereosinophilia: treatment with allogeneic cultured dermal substitute (CDS). Eur J Dermatol. 2004;14(3):168–71.PubMedGoogle Scholar
  55. 55.
    Jang KA, Lim YS, Cchoi JH, et al. Hypereosinophilic syndrome presenting as cutaneous necrotizing eosinophilic vasculitis and Raynaud’s phenomenon complicated by digital gangrene. Br J Dermatol. 2000;143(3):641–4.PubMedCrossRefGoogle Scholar
  56. 56.
    Bogenrieder T, Griese DP, Schiffner R, et al. Well’s syndrome as a manifestation of hypereosinophilic syndrome. Br J Dermatol. 1997;137(6):978–82.PubMedCrossRefGoogle Scholar
  57. 57.
    Tsuji Y, Kawashima T, Yokota K, et al. Well’s syndrome as a manifestation of hypereosinophilic syndrome. Br J Dermatol. 2002;147(4):811–2.PubMedCrossRefGoogle Scholar
  58. 58.
    Plötz SG, Abeck D, Behrendt H, et al. Eosinophilic cellulitis (Wells syndrome). Hautarzt. 2000;51(3):182–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Butterfield JH, Leifermann KM, Abrams J, et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood. 1992;79:688–92.PubMedGoogle Scholar
  60. 60.
    Banerji A, Weller PF, Sheikh J. Cytokine-associated angioedema syndromes including episodic angioedema with eosinophilia (Gleich’s syndrome). Immunol Allergy Clin North Am. 2006;26(4):769–81.PubMedCrossRefGoogle Scholar
  61. 61.
    Leiferman KM, Loegering DA, Gleich GJ. Production of wheal-and-flare skin reactions by eosinophil granule proteins. J Invest Dermatol. 1984;82:414.Google Scholar
  62. 62.
    Leiferman KM, Peter MS. Eosinophils in cutaneous diseases. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest B, Paller AS, Leffel DJ, editors. Fitzpatrick’s dermatology in general medicine, 7th ed, Chap 35. New York Chicago: McGraw-Hill, Inc.; 2008.Google Scholar
  63. 63.
    Jacyk WK, Simson LW, Slater DN, Leiferman KM. Pachydermatous eosinophilic dermatitis. Br J Dermatol. 1996;134:474–4698.CrossRefGoogle Scholar
  64. 64.
    Plötz SG, Simon HU, Ring J. Hautmanifestationen bei Hypereosinophiliesyndrom. Allergologie. 1998;21:489–98.Google Scholar
  65. 65.
    Plötz SG, Abeck D, Hein R, Ring J. High-dose UVA1 for hypereosinophilic syndrome. Arch Dermatol Res. 1998;290:81.Google Scholar
  66. 66.
    Butterfield JH, Gleich GJ. Interferon alpha treatment of six patients with the idiopathic hypereosinophilic syndromes. Ann Intern Med. 1994;121(9):648–53.PubMedGoogle Scholar
  67. 67.
    Hendren WG, Jones EL, Smith MD. Aortic and mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann Thorac Surg. 1988;46(5):570–1.PubMedCrossRefGoogle Scholar
  68. 68.
    Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18(4):734–42.PubMedCrossRefGoogle Scholar
  69. 69.
    Rotoli B, Catalano L, Galderisi M, et al. Rapid reversion of Loeffler’s endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. Leuk Lymphoma. 2004;45(12):2503–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1985;102(1):109–14.PubMedGoogle Scholar
  71. 71.
    Monaco S, Lucci B, Laperchia N, et al. Polyneuropathy in hypereosinophilic syndrome. Neurology. 1988;38(3):494–6.PubMedGoogle Scholar
  72. 72.
    Lefebvre C, Bletry O, Degoulet P, et al. Facteurs pronostiques du syndrome hypereosinophilique. Etude de 40 observations. Ann Med Interne (Paris). 1989;140:253–7.Google Scholar
  73. 73.
    Cordier JF, Faure M, Hermier C, Brune J. Pleural effusions in an overlap syndrome of idiopathic hypereosinophilic syndrome and erythema elevatum diutinum. Eur Respir J. 1990;3(1):115–8.PubMedGoogle Scholar
  74. 74.
    Levesque H, Elie-Legrand MC, Thorel JM, et al. Idiopathic hypereosinophilic syndrome with predominant digestive manifestations or eosinophilic gastroenteritis? a propos of 2 cases. Gastroenterol Clin Biol. 1990;14(6–7):586–8.PubMedGoogle Scholar
  75. 75.
    Scheurlen M, Mork H, Weber P. Hypereosinophilic syndrome resembling chronic inflammatory bowel disease with primary sclerosing cholangitis. J Clin Gastroenterol. 1992;14(1):59–63.PubMedCrossRefGoogle Scholar
  76. 76.
    Croffy B, Kopelman R, Kaplan M. Hypereosinophilic syndrome. Association with chronic active hepatitis. Dig Dis Sci. 1988;33(2):233–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Elouaer-Blanc L, Zafrani ES, Farcet JP, et al. Hepatic vein obstruction in idiopathic hypereosinophilic syndrome. Arch Intern Med. 1985;145(4):751–3.PubMedCrossRefGoogle Scholar
  78. 78.
    Eugene C, Gury B, Bergue A, Quevauvilliers J. Icterus disclosing pancreatic involvement in idiopathic hypereosinophilic syndrome. Gastroenterol Clin Biol. 1984;8(12):966–9.PubMedGoogle Scholar
  79. 79.
    Chaine G, Davies J, Kohner EM, et al. Ophthalmologic abnormalities in the hypereosinophilic syndrome. Opthalmology. 1982;89(12):1348–56.Google Scholar
  80. 80.
    Binaghi M, Perrenoud F, Dhermy P, et al. Hypereosinophilic syndrome with ocular involvement. J Fr Opthalmol. 1985;8(4):309–14.Google Scholar
  81. 81.
    Takekawa M, Imai K, Adachi M, et al. Hypereosinophilic syndrome accompanied with necrosis of finger tips. Intern Med. 1992;31:1262–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Trueb RM, Lubbe J, Torricelli R, et al. Eosinophilic myositis with eosinophilic cellulitis like skin lesions. Association with increased serum levels of eosinophil cationic proteins and interleukin-5. Arch Dermatol. 1997;133:203–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Trueb RM, Pericin M, Winzeler B, et al. Eosinophilic myositis/perimyositis: frequence and spectrum of cutaneous manifestations. J Am Acad Dermatol. 1997;37:385–91.PubMedCrossRefGoogle Scholar
  84. 84.
    Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome II: clinical manifestations. Blood. 1991;58:1021–6.Google Scholar
  85. 85.
    Flaum MA, Schooley RT, Fauce AS, Gralnick HR. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. Blood. 1981;58(5):1012–20.PubMedGoogle Scholar
  86. 86.
    Brugnoni D, Airo P, Rossi G, et al. A case of hypereosinophilic syndrome is associated with the expansion of a CD3− CD4+ T-cell population able to secrete large amounts of Interleukin-5. Blood. 1996;87:1416–22.PubMedGoogle Scholar
  87. 87.
    Busse WW, Ring J, Huss-Marp J, Kahn E. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. JACI. 2010;125(4):803–13.Google Scholar
  88. 88.
    Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2007;109(11):4635–40.PubMedCrossRefGoogle Scholar
  89. 89.
    Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124:1319–25.PubMedCrossRefGoogle Scholar
  90. 90.
    Chikama R, Hosokawa M, Miyazawa T, et al. Nonepisodic angioedema associated with eosinophilia. Report of 4 cases and review of 33 young female patients reported in Japan. Dermatology. 1998;197:321–5.PubMedCrossRefGoogle Scholar
  91. 91.
    Spigel T, Winkelmann RK. Wells’ syndrome. Arch Dermatol. 1979;115:611–3.PubMedCrossRefGoogle Scholar
  92. 92.
    Kamani N, Lipsitz PJ. Eosinophilic cellulitis in a family. Pediatr Dermatol. 1987;4:220–4.PubMedCrossRefGoogle Scholar
  93. 93.
    Peters MS, Schroeter AL, Gleich GJ. Immunofluorescence identification of eosinophil granule major basic protein in the flame figures of Wells’ syndrome. Br J Dermatol. 1983;109:141–8.PubMedCrossRefGoogle Scholar
  94. 94.
    Yagi H, Tokura Y, Matsushita K, et al. Well’s syndrome: a pathogenetic role for circulating CD4 + CD7− T-cells expressing Interleukin-5 mRNA. Br J Dermatol. 1997;136:918–23.PubMedCrossRefGoogle Scholar
  95. 95.
    Nir MA, Westfried M. Hypereosinophilic dermatitis. A distinct manifestation of the hypereosinopilie syndrome with response to dapsone. Dermatology. 1981;162:444–50.CrossRefGoogle Scholar
  96. 96.
    Schmelas A, Drobnitsch I, Schneider I. Hypereosinophilic dermatitis with response to ketotifen and sulfone. Dermatol Monatsschr. 1986;172(7):397–402.PubMedGoogle Scholar
  97. 97.
    Butterfield JH, Leifermann KM, Gleich GJ. Nodules, eosinophilia, rheumatism, dermatitis and swelling (NERDS): a novel eosinophilic disorder. Clin Exp Allergy. 1993;23:571–80.PubMedCrossRefGoogle Scholar
  98. 98.
    Pardanani A, Brockman SF, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104(10):3038–45.PubMedCrossRefGoogle Scholar
  99. 99.
    Kimura T, Yoshimura S, Ishikawa E. Unusual granulation combined with hyperplastic changes in lymphatic tissue. Trans Jpn Soc Pathol. 1948;13:179–80.Google Scholar
  100. 100.
    Kung IT, Gibson JB, Bannatyne PM. Kimura’s disease: a clinicopathological study of 21 cases and its distinction from angiolymphoid hyperplasia with eosinophilia. Pathology. 1984;16(1):39–44.PubMedCrossRefGoogle Scholar
  101. 101.
    Wang TF, Liu SH, Kao CH, et al. Kimura’s disease with generalized lymphadenopathy demonstrated by positron emission topography scan. Intern Med. 2006;45(12):775–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Chun SI. Kimura’s disease and ALHE with eosinophilia. J Am Acad Dermatol. 1992;27:954.PubMedCrossRefGoogle Scholar
  103. 103.
    Conelly A, Powell HR, Chan YF, et al. Vincristine treatment of nephrotic syndrome complicated by Kimura’s disease. Pediatr Nephrol. 2005;20(4):516–8.CrossRefGoogle Scholar
  104. 104.
    Braun-Falco M, Fischer S, Plotz SG, Ring J. Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab). Br J Dermatol. 2004;151(5):1103–4.PubMedCrossRefGoogle Scholar
  105. 105.
    Klion AD. Approach to the therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:551–60.PubMedCrossRefGoogle Scholar
  106. 106.
    Simon HU, Cools J. Novel approaches to therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:519–27.PubMedCrossRefGoogle Scholar
  107. 107.
    Klion AD, How I. treat hypereosinophilic syndromes. Blood. 2009;114:3736–41.PubMedCrossRefGoogle Scholar
  108. 108.
    Gleich GJ, Leifermann KM. The hypereosinophilic syndromes: current concepts and treatments. Br J Hematol. 2009;145:271–85.CrossRefGoogle Scholar
  109. 109.
    Van den Hoogenband HM, van den Berg WH, van Diggelson MW. PUVA-therapy in the treatment of skin lesions of the hypereosinophilic syndrome. Clin Exp Dermatol. 1985;7:267–72.CrossRefGoogle Scholar
  110. 110.
    Eberlein A, von Kobyletzki G, Gruss C, et al. Erfolgreiche Monotherapie der hypreosinophilen Dermatitis mit PUVA-Bad-Photochemotherapie. Hautarzt. 1997;11:820–43.CrossRefGoogle Scholar
  111. 111.
    Smit AJ, van Essen LH, de Vries EG. Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer. 1991;67:2826–7.PubMedCrossRefGoogle Scholar
  112. 112.
    Zielinski RM, Lawrence WD. Interferon alpha for the hypereosinophilic syndrome. Ann Intern Med. 1990;113:716–8.PubMedGoogle Scholar
  113. 113.
    Sefcick A, Sowter D, Da Gupta E, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol. 2004;124:558–9.PubMedCrossRefGoogle Scholar
  114. 114.
    Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009;15(1):268–73.CrossRefGoogle Scholar
  115. 115.
    Simon D, Braathen LR, Simon HU. Anti-interleukin-5 therapy for eosinophilic diseases. Hautarzt. 2007;122:124–7.Google Scholar
  116. 116.
    Leckie MF, ten Brinke A, Khan J, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356:2149–53.PubMedCrossRefGoogle Scholar
  117. 117.
    Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60:693–6.PubMedCrossRefGoogle Scholar
  118. 118.
    Kay AB, Klion AD. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome. Immunol Allergy Clin North Am. 2004;114:1449–55.Google Scholar
  119. 119.
    Klion AD, Robyn J, Maric I, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukaemia: implications for optimal dosing. Blood. 2007;110:3552–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Sabine Gisela Plötz
    • 1
    • 2
  • Bettina Hüttig
    • 1
  • Birgit Aigner
    • 2
  • Christian Merkel
    • 1
  • Knut Brockow
    • 1
  • Cezmi Akdis
    • 3
  • Ulf Darsow
    • 1
  • Johannes Ring
    • 1
    • 4
  1. 1.Department of Dermatology and Allergology am BiedersteinTechnical University Munich (TUM)MunichGermany
  2. 2.Dermatology Munich-HarlachingMunichGermany
  3. 3.Swiss Institute for Allergy and Asthma Research (SIAF)DavosSwitzerland
  4. 4.Christine Kühne Center for Allergy Research, Education (CK-CARE)Technical University MunichMunichGermany

Personalised recommendations